119 related articles for article (PubMed ID: 8804143)
21. An application of maximum likelihood and generalized estimating equations to the analysis of ordinal data from a longitudinal study with cases missing at random.
Kenward MG; Lesaffre E; Molenberghs G
Biometrics; 1994 Dec; 50(4):945-53. PubMed ID: 7787007
[TBL] [Abstract][Full Text] [Related]
22. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
Houck C
Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
[TBL] [Abstract][Full Text] [Related]
23. Application of pattern-mixture models to outcomes that are potentially missing not at random using pseudo maximum likelihood estimation.
Shen C; Weissfeld L
Biostatistics; 2005 Apr; 6(2):333-47. PubMed ID: 15772110
[TBL] [Abstract][Full Text] [Related]
24. A copula model for repeated measurements with non-ignorable non-monotone missing outcome.
Shen C; Weissfeld L
Stat Med; 2006 Jul; 25(14):2427-40. PubMed ID: 16143999
[TBL] [Abstract][Full Text] [Related]
25. Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease.
Schluchter MD; Greene T; Beck GJ
Stat Med; 2001 Apr; 20(7):989-1007. PubMed ID: 11276031
[TBL] [Abstract][Full Text] [Related]
26. Intent-to-treat analysis for longitudinal studies with drop-outs.
Little R; Yau L
Biometrics; 1996 Dec; 52(4):1324-33. PubMed ID: 8962456
[TBL] [Abstract][Full Text] [Related]
27. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
Gomeni R; Lavergne A; Merlo-Pich E
Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
[TBL] [Abstract][Full Text] [Related]
28. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
[TBL] [Abstract][Full Text] [Related]
29. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
31. An imputation strategy for incomplete longitudinal ordinal data.
Demirtas H; Hedeker D
Stat Med; 2008 Sep; 27(20):4086-93. PubMed ID: 18338313
[TBL] [Abstract][Full Text] [Related]
32. A high-dimensional joint model for longitudinal outcomes of different nature.
Faes C; Aerts M; Molenberghs G; Geys H; Teuns G; Bijnens L
Stat Med; 2008 Sep; 27(22):4408-27. PubMed ID: 18551509
[TBL] [Abstract][Full Text] [Related]
33. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
[TBL] [Abstract][Full Text] [Related]
34. [Fluoxetine versus fluvoxamine for treatment of chronic pain].
Ciaramella A; Grosso S; Poli P
Minerva Anestesiol; 2000; 66(1-2):55-61. PubMed ID: 10736983
[TBL] [Abstract][Full Text] [Related]
35. An index of local sensitivity to nonignorable drop-out in longitudinal modelling.
Ma G; Troxel AB; Heitjan DF
Stat Med; 2005 Jul; 24(14):2129-50. PubMed ID: 15909292
[TBL] [Abstract][Full Text] [Related]
36. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
Terra JL; Montgomery SA
Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185
[TBL] [Abstract][Full Text] [Related]
37. Statistical perspective on adjusting for center effect in a 2 x 2 crossover design with application to clinical trials.
Yue LQ
J Biopharm Stat; 2000 Nov; 10(4):559-71. PubMed ID: 11104393
[TBL] [Abstract][Full Text] [Related]
38. Dropouts versus completers among chronically depressed outpatients.
Arnow BA; Blasey C; Manber R; Constantino MJ; Markowitz JC; Klein DN; Thase ME; Kocsis JH; Rush AJ
J Affect Disord; 2007 Jan; 97(1-3):197-202. PubMed ID: 16857266
[TBL] [Abstract][Full Text] [Related]
39. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
Salim A; Mackinnon A; Christensen H; Griffiths K
Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
[TBL] [Abstract][Full Text] [Related]
40. Treatment of depression--newer pharmacotherapies.
Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
